Oncology and X-Ray products company
Varian Medical Systems
) recently revealed that medical practitioners at London's Harley
Street Clinic are utilizing its Calypso system to ensure timely
monitoring of tumors during prostate cancer radiotherapy sessions.
Calypso provides on-time data stream on the exact location of the
prostate, which can be otherwise difficult to target as it is known
to move by many millimeters during a therapy
ACCURAY INC (ARAY): Free Stock Analysis Report
VARIAN MEDICAL (VAR): Free Stock Analysis
To read this article on Zacks.com click here.
At Harley Street Clinic, doctors are utilizing the timely tracking
ability of Calypso to cut down the quantum of healthy cells facing
the beam. They place three Calypso transponders into the prostate,
which provide a stream of data. The location of the transponders is
monitored during treatment in order to regulate the focus of the
The Clinic reports that a growing number of patients are demanding
use of Calypso transponders during therapy. It foresees that
greater accuracy will cut radiation on healthy adjacent cells. This
will allow doctors to administer greater doses with higher
There are over 100 Calypso set ups worldwide and more than 15,000
patients have received therapy in conjunction with the system.
Varian is a leading manufacturer of integrated radiotherapy systems
for cancer treatment and a premier supplier of X-ray tubes for
diagnostic imaging applications. The company operates in a
technology-driven environment where success depends on the use of
new technology, product development and upgrades. In the radiation
oncology market, Varian competes with
The company is poised to increase its market share in radiation
oncology. It currently enjoys a healthy demand for its coveted
TrueBeam technology, which has meaningfully contributed to its net
order oncology growth. Varian's TrueBeam was designed to treat
tumors with beams of high speed and precision. It incorporates
several technological innovations such as patient positioning and
managing his/her motion. TrueBeam can dispense dosage roughly four
times faster than that possible with earlier equipment.
Moreover, Varian enjoys a strong balance sheet marked by low debt
and moderate cash. The company from time to time uses a part of its
healthy cash flow for share repurchases.
Varian competes with larger players in a technology-intensive
industry. Further, uncertainties stemming from health care reform
and a still weak hospital capital spending environment across many
developed countries, especially in Europe, are significant
We are currently 'Neutral' on Varian. The stock retains a Zacks #3
Rank, which translates into a short-term Hold rating.